IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by RWA Wealth Partners LLC

RWA Wealth Partners LLC trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,252 shares of the company’s stock after selling 50 shares during the period. RWA Wealth Partners LLC’s holdings in IDEXX Laboratories were worth $2,171,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership grew its position in shares of IDEXX Laboratories by 6.5% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 142,192 shares of the company’s stock valued at $58,788,000 after purchasing an additional 8,617 shares during the last quarter. Tsai Capital Corp grew its holdings in IDEXX Laboratories by 52.2% during the 4th quarter. Tsai Capital Corp now owns 8,797 shares of the company’s stock valued at $3,637,000 after buying an additional 3,016 shares during the last quarter. Allstate Corp purchased a new position in IDEXX Laboratories during the fourth quarter worth $1,009,000. DnB Asset Management AS raised its holdings in shares of IDEXX Laboratories by 1.8% in the fourth quarter. DnB Asset Management AS now owns 14,675 shares of the company’s stock worth $6,067,000 after acquiring an additional 254 shares during the last quarter. Finally, Pictet Asset Management Holding SA boosted its stake in shares of IDEXX Laboratories by 23.4% during the fourth quarter. Pictet Asset Management Holding SA now owns 442,484 shares of the company’s stock valued at $182,941,000 after acquiring an additional 83,964 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

IDXX stock opened at $415.87 on Monday. The stock has a 50-day moving average price of $437.07 and a two-hundred day moving average price of $442.57. The company has a market cap of $33.71 billion, a PE ratio of 38.98, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Barclays boosted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Morgan Stanley reduced their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, March 25th. Finally, Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.